

| Catalog No. | HY127026 |
|---|---|
| Description |
Efzimfotase Alfa (HY127026) is a research-grade recombinant antibody targeting Alkaline phosphatase liver/bone/kidney isozyme. Produced in mammalian cells with native-like glycosylation.
Highlights
|
| Species reactivity | Human |
| Applications | ELISA, Functional assay, Research in vivo |
| Isotype | Human alkaline phosphatase, tissue-nonspecific isozyme/AP-TNAP soluble fragment fused to a human immunoglobulin G4 heavy chain constant region fragment fused to a deca-aspartate peptide, disulfide bridged dimer. |
| Expression system | Mammalian cells |
| Clonality | Monoclonal |
| Target | Alkaline phosphatase liver/bone/kidney isozyme, AP-TNAP, TNSALP, Alkaline phosphatase, tissue-nonspecific isozyme, ALPL |
| Endotoxin level | Please contact the lab for this information. |
| Purity | >95% purity as determined by SDS-PAGE. |
| Purification | Purified by Nickel column. |
| Accession | P05186 |
| Form | Liquid |
| Storage buffer | 0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Alternate Names | 2746354-58-3 |
| Background | Alkaline phosphatase, tissue-nonspecific isozyme (ALPL) is a ~57 kDa protein. Alkaline phosphatase that metabolizes various phosphate compounds and plays a key role in skeletal mineralization and adaptive thermogenesis. Has broad substrate specificity and can hydrolyze a considerable variety of compounds: however, only a few substrates, such as diphosphate (inorganic pyrophosphate; PPi), pyridoxal 5'-phosphate (PLP) and N-phosphocreatine are natural substrates. Plays an essential role in skeletal and dental mineralization via its ability to hydrolyze extracellular diphosphate, a potent mineralization inhibitor, to phosphate: it thereby promotes hydroxyapatite crystal formation and increases inorganic phosphate concentration. Acts in a non-redundant manner with PHOSPHO1 in skeletal mineralization: while PHOSPHO1 mediates the initiation of hydroxyapatite crystallization in the matrix vesicles (MVs), ALPL/TNAP catalyzes the spread of hydroxyapatite crystallization in the extracellular matrix. Also promotes dephosphorylation of osteopontin (SSP1), an inhibitor of hydroxyapatite crystallization in its phosphorylated state; it is however unclear whether ALPL/TNAP mediates SSP1 dephosphorylation via a direct or indirect manner. 1. Di Mauro, S. et al. (2002) Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 17, 1383-91. PMID: 12162492 2. Sultana, S. et al. (2013) Molecular genetics and metabolism 109, 282-8. PMID: 23688511 3. Numa-Kinjoh, N. et al. (2015) Molecular genetics and metabolism 115, 180-5. PMID: 25982064 4. Fedde, KN. et al. (1990) American journal of human genetics 47, 767-75. PMID: 2220817 5. Balasubramaniam, S. et al. (2010) Journal of inherited metabolic disease 33 Suppl 3, S25-33. PMID: 20049532 6. Pettengill, M. et al. (2017) PloS one 12, e0175936. PMID: 28448526 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |

SDS-PAGE for Research Grade Efzimfotase Alfa
Contact us for custom quotes, bulk requests and any other issues.
Mail: support@abinScience.com


+86-27-87433958
Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China
中文
English
한국어
日本語
Español
Français
Русский